Skip to content

Clinical study to evaluate efficacy of Dabur Chyawanjunior in comparison with Bournvita in overallgrowth of primary school going children

An open randomized prospective clinical study to evaluate comparative efficacy of DRF/AY/5023 with Bournvita in overallgrowth of children attending primary school

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/08/009320
Enrollment
160
Registered
2017-08-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Chyawan Junior: Health supplement in the form granules having chocolate colour. 2 tea spoonful with glass of milk, twice daily for 6 months Control Intervention1: Bournvita: Health supp

Sponsors

Dabur India Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male & female children with age not more than 12 years. 2. Medically stable with no requirement of drugs,or any interventions/procedures or any neutraceutical / health supplement. 3. Permission was obtained from the parents of all children and willing to sign an informed consent. 4. Parents and teacher of the child willing to sign an informed consent

Exclusion criteria

Exclusion criteria: 1. Children with any underlying physical or mental illness. 2. Children who required use of concomitant medications known to adversely interact with study drug. 3. Known Hypersensitivity to study drug or ingredients in the study drug 4. Required use of concomitant medication known to adversely interact with study drug 5. Subjects participating in other clinical trials 6. Parents and teachers of the children not willing to sign Informed Consent

Design outcomes

Primary

MeasureTime frame
To assess the efficacy in overall growth and health of childrenTimepoint: Anthropometry Scale, Wechsler Intelligence Scale for Children (WISC, Record of schcoll attendance (Monthly), School performance & subjective parameters such as taste evaluation, Physician global evaluation for overall growth, Parents global evaluation for overall growth at Visit 1(4 weeks from baseline), Visit 2(8 weeks from baseline), Visit 3(12 weeks from baseline), Visit 4(16 weeks from baseline), Visit 5(20 weeks from baseline) and Visit 6(24 weeks from baseline)

Secondary

MeasureTime frame
To assess the efficacy of Dabur Chyawanjunior in general intelligence and school performance compared with bournvita. To assess the the overall palability and likeability of Dabur Chyawanjunior and bournvita. To assess the safety of Dabur ChyawanjuniorTimepoint: 4,8,12,16,20,24 weeks from baseline

Countries

India

Contacts

Public ContactDr Arun Gupta

Dabur India Limited

arun.gupta@dabur.com01203378614

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026